HIV-PASS (Pain and Sadness Support): Randomized Controlled Trial of a Behavioral Health Intervention for Interference Due to Pain in People Living With HIV, Chronic Pain, and Depression.
HIV-PASS (Pain and Sadness Support): Randomized Controlled Trial of a Behavioral Health Intervention for Interference Due to Pain in People Living With HIV, Chronic Pain, and Depression.
复制标题
HIV-PASS（疼痛和悲伤支持）：对艾滋病毒感染者、慢性疼痛和抑郁症患者的疼痛进行行为健康干预的随机对照试验。
DOI：
10.1097/psy.0000000000001172
复制
发表时间：
2023
影响因子：
3.3
通讯作者：
Stein,MichaelD
中科院分区：
文献类型：
--
作者：
Uebelacker,LisaA;Pinkston,MeganM;Busch,AndrewM;Baker,JasonV;Anderson,Bradley;Caviness,CelesteM;Herman,DebraS;Weisberg,RisaB;Abrantes,AnaM;Stein,MichaelD
ObjectiveThis study aimed to determine whether HIV-Pain and Sadness Support (HIV-PASS), a collaborative behavioral health intervention based on behavioral activation, is associated with decreased pain-related interference with daily activities, depression, and other outcomes in people living with HIV.MethodsWe conducted a three-site clinical trial (n= 187) in which we randomly assigned participants to receive either HIV-PASS or health education control condition. In both conditions, participants received seven intervention sessions, comprising an initial in-person joint meeting with the participant, their HIV primary care provider and a behavioral health specialist, and six, primarily telephone-based, meetings with the behavioral health specialist and participant. The intervention period lasted 3 months, and follow-up assessments were conducted for an additional 9 months.ResultsCompared with health education, HIV-PASS was associated with significantly lower pain-related interference with daily activities at the end of month 3 (our primary outcome; b=− 1.31, 95% confidence interval=− 2.28 to− 0.34). We did not observe other differences between groups at 3 months in secondary outcomes that included worst or average pain in the past week, depression symptoms, anxiety, and perceived overall mental and physical health. There were no differences between groups on any outcomes at 12 months after enrollment.ConclusionsA targeted intervention can have positive effects on pain interference. At the end of intervention, effects we found were in a clinically significant range. However, effects diminished once the intervention period ended.
